Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients

Table 2 Serological associations with anti-tumor necrosis factor adverse reactions in patients with ulcerative colitis and Crohn’s disease (anti-I2, anti-Pseudomonasfluorescens-associated sequence I2; ASCA, anti-Saccharomyces cerevisiae antibodies)

IBD type	Adverse event	Serological marker	Serology levels in positive (U/mL)	Serology levels in negative (U/mL)	P value
CD	Any	IgA ASCA	7	10	0.040
CD	Any	IgG ASCA	18	26.5	0.020
UC	Infusion	Anti-I2	0	7	0.008

IBD: Inflammatory bowel disease; CD: Crohn’s disease; UC: Ulcerative colitis.